Emezine FDA Approval Status
Emezine is a buccal tablet formulation of prochlorperazine maleate intended for the treatment of severe nausea and vomiting.
In March 2006, BioDelivery Sciences International, Inc. announced the receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for Emezine (prochlorperazine maleate) had not been approved.
Development Timeline for Emezine
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.